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Monitoring global health: time for new solutions
Christopher J L Murray, Alan D Lopez, Suwit Wibulpolprasert
Improved global health monitoring requires new technologies and methods, strengthened national
capacity, norms and standards, and gold standard global reporting. The World Health Organization’s
many functions limit its capacity for global reporting, and a new global health monitoring
organisation is needed to provide independent gold standard health information to the world
Sound information on financial and human resources
invested in health, health interventions delivered to
people in need, and the impact of these efforts on peo-
ple’s health is critical for planning health systems,
implementing programmes, epidemic response, allo-
cating budgets for research and development,monitor-
ing progress, and evaluating what works and what does
not. Although all countries collect a wide range of
health information through registries, surveys, and
vital registration systems, huge gaps hinder our ability
to respond to global health challenges, which are
alarming at a time when global investments in AIDS,
tuberculosis, and malaria are increasing and when
there is renewed focus on health goals as exemplified
by the UN Millennium Declaration.1
The availability of valid, reliable, and comparable
health information to inform local, regional, national,
and global decisions can be furthered through four
interconnected efforts: improving the technology and
methods for population health measurement;
strengthening national capacity and motivating gov-
ernments to collect and analyse useful health data;
establishing global norms and standards for what are
the core health related measurements and how to
measure them; and reporting to the globe valid,
reliable, and comparable assessments of inputs, service
delivery, and achievements for health. Although many
challenges and initiatives are under way for the first
three of these components, the fourth area is currently
the weakest and getting worse, not better. We explore
the problem and the potential solution to global moni-
toring and evaluation and briefly review the other
three areas as necessary.
Technology and methods of health
measurement
For several critical measures of health, delivery of
interventions, and financial and human resources
including many millennium development goal indica-
tors, the current measurement technology is inad-
equate. Although validated methods have been
developed to measure child mortality through
household surveys in settings where vital registration is
incomplete or non-existent,2-4 no adequate method
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exists to measure adult mortality in such settings.5
Although antibody tests for HIV mean that the
prevalence of infection in the population can be ascer-
tained from sample surveys,6 no affordable and feasible
methods are currently available to assess tuberculosis in
a community. Advances in immunology, proteomics,
genomics, metabolomics, survey science, and statistical
methods may result in new technologies or methods
coming on line in the next decade that will dramatically
improve our ability to monitor population health.7
Strengthening capacity
Strengthening national capacity to collect and analyse
data is essential. Intense efforts have been made to
strengthen data collection for particular vertical
disease programmes, such as polio eradication8 or
selected sentinel communities,9 but progress in
national collection of health data and capacity for
analysis in low income and many middle income coun-
tries has been slow. One exception is the development
of the ThaiHealth Foundation, where a 2% excise tax
on tobacco and alcohol funds a major programme for
improvement in the national health information
system. Investments and efforts at technical assistance
to build national health information capacity have
continued over the past 30-40 years, with only limited
success.10 11 Efforts to strengthen national capacity may
be invigorated by the Health Metrics Network
(www.who.int/healthmetrics), which seeks to catalyse
the development of health information systems in
developing countries. In current plans, the network will
focus on capacity building in five to seven countries per
year. The World Health Organization along with other
partners has a lead role in providing technical
assistance and guidance in developing national capac-
ity for health information. Progress is often hindered
by the difficulty of showing to national decision makers
that good health data can strongly support decision
making. In our experience, enhanced global reporting
will increase government commitment to collect high
quality data.
Norms and standards
A third building block for effective health information
is the establishment of global norms and standards on
key indicators for different health programmes and for
health systems overall, the best measurement methods
for these indicators given current technology and ana-
lytical methods, and standardised definitions and clas-
sification systems. As illustrated by the International
Classification of Diseases and Injuries over the past 50
years, WHO can play a powerful part in all this.12 For
overall health statistics and many disease specific or
risk factor specific areas, WHO can and should remain
the leading institution. Nevertheless, WHO has shifted
away from work on global norms and standards to
emphasise country implementation of disease pro-
grammes,13 which will create a void that other
institutions may need to fill.
Global reporting
The fourth component—critical if health information
is to have an impact locally, nationally, or globally—is
the creation and dissemination of gold standard infor-
mation on key indicators of inputs, achievements, and
impacts of health interventions. Reporting informa-
tion that is valid and reliable and can be benchmarked
meaningfully is essential for monitoring progress and
evaluating what works and what does not. Unless
health information is disseminated to the public, the
scientific and public health community, and decision
makers through multiple channels, including the
media, scientific journals, and other documents, it
more often than not remains unused in statistical
abstracts or spreadsheets in health ministries.
The sum of deaths
claimed by different
WHO programmes
exceeded the total
number of deaths in
the world
WHO is the major actor in global health reporting
because it is the leading agency in the United Nations
system working on health and because in many cases
no credible alternative exists. In some cases, WHO
undertakes this reporting function in partnership with
others such as UNICEF or UNAIDS, but at present the
default expectation is that WHO should report gold
standard information to the world. Because of this
expectation, we focus much of our analysis of global
health reporting on the structural challenges that
WHO faces in this role before proposing potential
solutions.
Over time and across technical areas, WHO’s
performance in global reporting has varied tremen-
dously. For example, for child and adult mortality,
WHO has made systematic efforts to collate and
analyse all available data sets14 and has published
abridged life tables for all countries.15 In contrast, for
one of the millennium development goal indicators,
the prevalence of malaria, WHO simply reports coun-
try statistics irrespective of a wide range of known
biases. As a consequence, Nigeria has a rate of 30 cases
per 100 000 per year and Guatemala has 386/100 000.
At a fundamental level, the architecture of global insti-
tutions has an essential flaw with regards to monitoring
and evaluation, which must be addressed. We identify
the core reasons for this problem and offer potential
solutions. Addressing the problems with global report-
ing will, we believe, also fuel greater commitment
among countries to strengthening national health
information systems.
Too many roles for WHO
WHO very often finds itself in the multiple roles of
global advocate, provider of technical assistance to
countries, monitor of progress towards targets, and
evaluator of what works and what does not. The
commitment and dedication of WHO’s staff working
in the technical departments is unquestionable.
The problem is that staff representatives inevitably
feel the tension between advocacy, monitoring, and
evaluation. In other arenas, such as business, it would
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be unthinkable to ask a company to audit themselves.
Two examples can serve to illustrate the consequences
of this problem.
In the early 1990s, the global burden of disease
study was initiated in part because the sum of deaths
claimed by different WHO programmes exceeded the
total number of deaths in the world several times.16 The
intense pressure on technical programmes to keep
their figures as large as possible was evident. Crudely,
size of problem often translated into dollars from
donor agencies. The global burden of disease study,
published in 1996, set new benchmarks for internal
consistency, comparability, and comprehensiveness of
epidemiological information.17
Since 1998, WHO has adopted and implemented
the study’s approach to producing coherent epidemio-
logical information. Given the importance of figures
for advocacy, technical programmes would exert
intense competitive pressure on the epidemiology and
burden of disease team that was charged with bringing
together WHO’s annual assessments. These pressures
were withstood because of the strong commitment of
the senior management to valid, reliable, and
comparable epidemiological information. This proc-
ess, although imperfect, meant that internally consist-
ent, comparable, and comprehensive information on
incidence, prevalence, mortality, and disabling seque-
lae by age and sex for 14 epidemiological subregions
of the world were published each year. Over the past
year, as the focus of WHO has shifted to technical
assistance for countries, the epidemiology and burden
of disease team has been reduced from 22 to two staff
members, and it seems unlikely that the effort to
produce coherent comparable epidemiological data by
major causes of death and ill health will continue.
WHO’s tuberculosis programme provides another
example of the tensions that inevitably exist in an
organisation simultaneously developing advocacy
material, providing countries with technical assistance,
monitoring progress towards the global targets, and
evaluating its own directly observed treatment, short
course (DOTS) strategy. Direct measurements of tuber-
culosis in populations come from four potential
sources: registered tuberculosis deaths, notified new
cases of tuberculosis, purified protein derivative stand-
ard (PPD) skin testing of BCG scar negative children,
and sputum prevalence surveys. For most low income
countries, the only source is case notifications. WHO
has estimated true incident cases from case notifica-
tions.18 19 Such estimates are useful for planning
purposes but should not be used for monitoring
progress or evaluating the DOTS strategy. In many
countries, case notifications are being used to calculate
the numerator of the case detection rate and to
estimate the denominator. Trends in case detection
(one of two key indicators for tuberculosis pro-
grammes) are derived exclusively from changes in the
assumptions.
The figure shows, by using isoquants, all possible
combinations of true incidence and case detection
rates that are consistent with the number of notified,
smear positive cases of tuberculosis in Mozambique for
each year from 1996 to 2002. The choice of a unique
combination of true incidence and case detection rates
from each year’s isoquant is arbitrary.WHO has a set of
assumptions on which it bases the case detection rates
for each year. As estimates for a given year are
arbitrary, estimates of trends in case detection rates
over time have no empirical basis—the isoquants in the
figure are consistent with increasing or decreasing
trends in case detection rates, and no information is
available on the true trend. It should also be noted that
WHO’s assumed case detection rates and true
incidence for the same year differ in the published glo-
bal tuberculosis reports and on its website.20 Serial
guessing is not a sound basis for monitoring progress
towards a global target of 70% case detection. Because
the WHO programme is also the global advocate for
tuberculosis control, it cannot and does not bring
attention to the fact that essentially no empirical basis
exists to assess the trend in case detection in regions
where tuberculosis is most prevalent, including
sub-Saharan Africa.
National politics and impossible figures
WHO is a voluntary association of sovereign states; its
owners are the 192 member states. More practically,
strategy is set by the ministers of health or their repre-
sentatives, who attend the executive board twice a year,
and to the World Health Assembly in May of each year.
Irrespective of legal mandates, if a powerful country
disputes country specific figures produced by WHO, it
can bring strong pressure to bear on the organisation
to change the data. Everyone who has worked in a sen-
ior position in the United Nations recognises this
problem.
A standard compromise used in the UN, including
WHO, is to report regional figures that have been ana-
lysed and corrected for known biases and national fig-
ures that are simply the figures sent by member states.
This situation produces many examples of bizarre
results. Regional totals of disease incidence or patients
receiving treatment often do not equal the sum of pub-
lished country specific figures. Another example is the
publication of impossible figures, such as case
detection rates for smear positive tuberculosis greater
than 100% for Oman, Chile, Honduras, and Algeria,
among others.20 How can we believe any of the national
figures published for case detection if rates over 100%
are accepted without scrutiny?
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As novel institutions such as the Global Alliance for
Vaccines and Immunizations and the Global Fund for
AIDS, Tuberculosis and Malaria propose to link
disbursements to achievements in delivering interven-
tions, the pressure at the national level to provide
biased data will intensify. Even before the global
alliance, no relation existed between reported changes
in immunisation coverage and changes as measured
through household surveys.21 The global alliance
recognises the potential problem of providing
performance related disbursements and asking recipi-
ents if they have achieved their targets.22 Its data quality
audits show profound problems and opportunities for
distortion.23 Still, vaccine coverage has not been
accessed independently. The same problems will apply
to investments of the global fund.
Pressure from countries on WHO’s leadership
means a constant possibility that monitoring and evalu-
ation can be distorted. The experience during the severe
acute respiratory syndrome (SARS), when strong WHO
leadership withstood pressure from both China and
Canada and issued travel warnings, shows that
courageous leadership can withstand political pressure.
The experience of SARS and outbreaks more generally
points to two different dimensions of the problem.
Firstly, WHO may be able to resist political
pressures for brief periods of time, but this becomes
increasingly difficult as the time span gets longer.
Because many reports of outbreaks are picked up from
local media reports and not national governments,24 25
and because of the intense media focus on outbreaks,
the time available for political pressure on WHO lead-
ership is much shorter. It seems likely that WHO can,
especially with strengthened international health regu-
lations,26 fulfil the need for reporting global outbreaks.
However, for monitoring inputs to health systems,
delivery of health interventions for a wide range of
programmes, and progress on overall health, the
dynamics are different. As the time frame is longer, the
potential for manipulating the data is much greater.
Secondly, structural problems of monitoring and
evaluation for organisations such as WHO can be
overcome temporarily or at least attenuated by strong
leadership. But we cannot expect always to have
organisational leadership that is willing to take on this
challenge. We should recognise the important roles of
WHO in building national capacity for health informa-
tion, establishing norms and standards for measure-
ment, and setting agendas for research and develop-
ment on new technologies and methods. At the same
time, we have to recognise that WHO is ill suited for
the role of global monitoring and evaluation of health.
Potential solutions
To sustain increased investments in global health, gold
standard information is essential. In the long run, such
information will require better measurement methods
and technologies, capacity strengthening in develop-
ing countries, and global norms and standards. To ful-
fil our need for gold standard information in the short
term and to fuel government commitment to better
health information in the long term, the institutional
problems of global reporting by WHO and other UN
agencies need to be solved. Although our analysis has
stressed the structural issues of WHO, the problems of
mixing advocacy, technical assistance, monitoring and
evaluation roles, and maintaining independence from
country pressure apply to other agencies and
organisations as well.
Solutions such as creating an independent arm of
the WHO that reports directly to the executive board,
a strategy adopted by the World Bank and the Interna-
tional Monetary Fund, are possible but pose nearly
insurmountable political challenges. Initiatives that are
specific to a disease or intervention to undertake inde-
pendent monitoring to a gold standard may be helpful
but will miss out on the many opportunities for
improved global reporting that are common across
programmes. We believe that the only viable solution
will be to create a new, independent, health monitoring
organisation.
The objective of this body would be to report
regularly to the world on what is spent on health, what
health services are delivered, and the impact of these
efforts on population health. This organisation would be
small as its main role would be to collate, analyse, and
disseminate the best available evidence. Much of this
work would be in close partnership with various actors
such as the WHO technical programmes, the Global
Alliance for Vaccines and Immunizations, and the
Global Fund for AIDS, Tuberculosis and Malaria. To be
effective, the organisation would need to be as sheltered
as possible from the needs of advocacy on the one hand
and country political interference on the other.
Those familiar with the complex governance issues
that new entities such as the global alliance or the glo-
bal fund have faced will recognise that solving the gov-
ernance and financing issues for this organisation will
not be easy, but it can be done. Success of such an
organisation would depend on several key factors.
Firstly, all representatives from the key stakeholders in
global reporting would need to have a voice in the gov-
ernance of this effort. Key stakeholders would include
national governments, multilateral institutions (WHO,
UNICEF, UNAIDS, UN Development Programme,
World Bank, European Union, and others), bilateral
donor agencies, a range of non-governmental organi-
sations, and the research community.
Secondly, to be effective such a health monitoring
organisation would have to be committed to the prin-
ciples of validity, reliability, comparability of figures, an
Experience with the SARS outbreak shows that courageous leadership can withstand political
pressure
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explicit data audit trail, and open consultation. As
health information reaches a wider audience and
touches on issues salient to everybody’s life, scrutiny of
this information will intensify. The criticisms of the
World Health Report 2000 and the subsequent
recommendations of the scientific peer review
group27-29 highlight the importance of total transpar-
ency in the process of measurement.
Validity and reliability are familiar concepts in
health measurement. Comparability means that results
should be reported in a manner that allows meaningful
comparisons to be made between countries and over
time. Committing to an explicit data audit trail is costly
but essential. This means that every step in the
development of a figure should be made publicly avail-
able, including the primary data, details on the
methods used to analyse the primary data (including
corrections for known biases), and adequate documen-
tation of all steps in the analysis. The extraordinary
commitment of the Human Genome Project to put all
primary data in the public domain with effectively no
time lag should be held up as a model to follow. Finally,
open consultation means that both governments and
the scientific community at large should be able to
comment and critique figures that are published.
Fostering healthy debate on measurements will lead to
better data collection and analysis.
Thirdly, an independent monitoring organisation,
although it could be a relatively small undertaking of the
order of $50m-70m (£27m-38m;€39m-55m) per year,
would require stable core resources. Securing the right
combination of governance and stable core resources is
the main challenge for creating such an organisation.
Without core resources, any organisation—regardless of
governance structure—could be captured by its agencies
that fund specific projects. Several financing models
would be possible, ranging from endowment to assessed
contributions from entities that would benefit from the
dissemination of gold standard information to revenue
generating services such as accreditation of figures.
In an era when the credibility of global health
organisations is under attack, providing the public with
credible, clear, and comparable health information will
strengthen the commitment and resolution to scale up
efforts on global health. At the Bangkok AIDS confer-
ence in July 2004, a journalist asked whether WHO
figures on the delivery of antiretroviral therapy were
“‘Enron’-like.”30 Although such comments are clearly
unfair, doubts about what has been achieved and
whether we are pursuing the right strategies to make
progress could undermine the consensus that invest-
ing in global health is vital. It is in the interest of all of
the global community to invest in solid independent
monitoring and reporting.
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Summary points
Improved global health monitoring requires new technologies and
methods, strengthened national capacity, norms and standards, and
gold standard global reporting
WHO’s ability to undertake independent global reporting is limited
by its simultaneous roles as global advocate, technical adviser to
countries, monitor, and evaluator—and by intense political pressure
A new global health monitoring organisation is needed to provide
independent gold standard health information to the world
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leukaemia16) were not predicted by animal studies
using similar doses of vector.
One set of questions on toxicology related to gene
transfer arises because most studies in humans—as
with many other trials of hazardous agents—enrol par-
ticipants with advanced illness. Such participants are
likely to misinterpret the purpose of the trial as provid-
ing therapy rather than producing generalisable
knowledge.17 Enrolment in studies on the safety of
gene transfer is therefore susceptible to being based on
“misinformed” consent. Also, participants who per-
ceive a trial as providing therapy may be less willing to
comply with intrusive procedures (for example, long
term follow up and autopsy) that are aimed at testing
safety. By policing consent procedures for language
that promotes misconceptions about therapy, investi-
gators may encourage participants to cooperate with a
trial’s toxicological aspects.18
Premarketing studies of drugs often have insuffi-
cient power to expose rare adverse events19; the collec-
tion of toxicity data is further hampered because gene
transfer trials generally enrol participants with severe
illness. For instance, attributing causes for adverse
events is confounded by underlying medical conditions.
Moreover, such populations are unlikely to survive and
experience theoretically predicted latent adverse events.
Therefore, many risks will only be characterised once
gene transfer extends to populations with less severe
medical conditions; patients and the public (rather than
trial participants) will likely bear many of the risks
involved in characterising latent toxicity.
Owing to the uncertainties and inexperience
surrounding risks from gene transfer, systems may
need to be established for postmarketing surveillance
(for example, registries) and the long term follow up of
trial participants. In the United States, such long term
follow up is not mandatory, and anecdotal evidence
indicates that it is not widely practised.18 In contrast, the
United Kingdom20 and Australia (www7.health.gov.au/
nhmrc/research/gtrap.htm) track the medical records
of recipients of gene transfer. Follow up and post-
marketing surveillance are potentially costly, can medi-
calise people’s lives, and infringe on their privacy.
Nevertheless, spontaneous reporting of adverse events
is unreliable for detecting latent adverse events,19 and
more active measures may be necessary to protect the
public, and patients and their descendants, should
gene transfer expand to milder medical conditions.
Although recent trials confirm the feasibility of
gene therapy, they also highlight that its risks are
poorly understood. The task for researchers in gene
transfer will be to characterise these risks while attend-
ing to the complex ethical challenges of conducting
gene transfer studies in humans.
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Corrections and clarifications
The next small step
The author of this article in our Christmas issue,
Kevin Fong, has notified us that his email address
is missing its first full stop (BMJ 2004;329:1441-4,
18-25 Dec). His correct address is k.fong@ucl.ac.uk.
Monitoring global health: time for new solutions
The authors of this Education and Debate article
(who argued that a new global health monitoring
organisation is needed to replace the World Health
Organization) would like to clarify for readers that
they have all had recent links with WHO
(BMJ 2004;329:1096-100, 6 Nov). Christopher J L
Murray worked for WHO until 15 September 2003,
Alan D Lopez worked for the organisation until
1 January 2002, and Suwit Wibulpolprasert has
served on a number of advisory committees to WHO.
If the honey doesn’t get you, the bees will
A lapse in concentration by Harvey Marcovitch, the
author of the summaries on the BMJ Family
Highlights page, led to the inadvertent omission of
the word haemorrhagic in this summary on the
BMJ Family Highlights page (BMJ 2004;329:1368,
11 Dec). The third sentence should have read:
“Computed tomography of the head and magnetic
resonance imaging of the brain showed a large
right temporo-occipital haemorrhagic infarct.”
Cadavers as teachers: the dissecting room experience in
Thailand
In this article by Andreas Winkelmann and Fritz H
Güldner in our Christmas issue, we forgot to carry
out the authors’ wishes that we acknowledge
Professor G H Schumacher from Rostock,
Germany, as the provider of the photograph
(BMJ 2004;329:1455-7, 18-25 Dec).
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